Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Risedronate].

Yasuhiko Ogura1, Hisao Nakajima

  • 1Associete General Manager, Clinical Development Department, Phamaceutical Company, Ajinomoto Co., Inc.

Clinical Calcium
|March 19, 2005
PubMed
Summary

Risedronate, a potent osteoporosis drug, significantly reduces hip and vertebral fracture risks by up to 50% and increases bone density. It demonstrates a favorable safety profile, with no increased gastrointestinal issues compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Efficacy and Safety of Rezum® Water Vapor Therapy for Treating Urinary Retention: Analysis of 34 Cases in Japan].

Hinyokika kiyo. Acta urologica Japonica·2025
Same author

Symptom-Based Testosterone Therapy in Japanese Men With Late-Onset Hypogonadism Syndrome: A Real-World Single-Arm Study Following the 2022 Guideline.

International journal of urology : official journal of the Japanese Urological Association·2025
Same author

One hundred cases of Rezum water vapor thermal therapy for benign prostatic hyperplasia: Real-world data at a single institution in Japan.

International journal of urology : official journal of the Japanese Urological Association·2024
Same author

Improving Antibiotic Administration Rate for Patients With Sepsis in the Emergency Department.

Journal of nursing care quality·2021
Same author

[A Case of General Fatigue Caused by Enzalutamide that was Evaluated Using the Cancer Fatigue Scale and Overcome by Switching to Nighttime Treatment].

Hinyokika kiyo. Acta urologica Japonica·2020
Same author

Serum testosterone levels using the radioimmunoassay method in healthy Japanese male volunteers.

Reproductive medicine and biology·2018

Area of Science:

  • Pharmacology
  • Orthopedics
  • Bone Metabolism

Context:

  • Osteoporosis treatment landscape.
  • Risedronate's approval and classification as a third-generation bisphosphonate.
  • Need for effective anti-resorptive therapies.

Purpose:

  • To evaluate the efficacy and safety of risedronate in osteoporosis treatment.
  • To assess fracture risk reduction and bone mineral density changes.
  • To compare risedronate's gastrointestinal safety profile with placebo.

Summary:

  • Risedronate, a potent bisphosphonate, demonstrated significant reductions in hip (approx. 30%) and vertebral (approx. 50%) fracture risks over three years compared to placebo.
  • Treatment with risedronate led to a notable increase in lumbar spine bone mineral density (BMD) of around 5% at one year.
  • Bone turnover markers decreased by up to 40%, indicating potent anti-resorptive activity, with histologically normal bone formation observed.

Impact:

  • Risedronate offers a clinically important reduction in fracture risk for osteoporosis patients.
  • The drug shows a favorable safety profile, with no increased upper gastrointestinal adverse events compared to placebo in pooled analyses.
  • Provides a valuable therapeutic option for managing osteoporosis and preventing fractures.

Related Experiment Videos